Af­ter last year's suc­cess­ful $10 bil­lion sale of Met­sera, and then the launch of an in­flam­ma­to­ry dis­ease biotechear­li­er this year, ARCH Ven­ture Part­ners...

UniQure's shares QURE were rocked Tues­day morn­ing af­ter the com­pa­ny re­vealed its ex­per­i­men­tal Hunt­ing­ton’s dis­ease gene ther­a­py may have less ben­e­fit than orig­i­nal­ly thought.

In...

A trio of for­mer AI sci­en­tists and en­gi­neers at Roche's Genen­tech has start­ed a com­pa­ny called Or­tet, with vi­sions of chang­ing the health­care sys­tem with...

Drug­mak­ers and in­vestors have ramped up their spend­ing and R&D at­ten­tion on au­toim­mune dis­eases in re­cent years, with a pro­lif­er­a­tion of bis­pe­cif­ic T cell en­gagers...

SK pharmte­co plans to spend at least $200 mil­lion on build­ing out its de­vel­op­ment and man­u­fac­tur­ing in­fra­struc­ture over the next five years, which is ex­pect­ed...